Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Geron CorporationNASDAQ: GERN
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $4.91M fell 33.8% year over year, ahead of the -65.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 33.8% from the prior quarter. Over 3 fiscal years it compounded at -77.8% a year.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 40.6 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.8% holds above the trailing-twelve-month pace of -65.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 88K USD
- Year-over-year change
- -99.7%
- 4-year CAGR
- -67.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 88K | -99.7% |
| FY2024 | 2024-12-31 | 31.32M | +61.8% |
| FY2023 | 2023-12-31 | 19.35M | +141.9% |
| FY2022 | 2022-12-31 | 8M | -1.0% |
| FY2021 | 2021-12-31 | 8.08M | — |
Stock-Based Compensation vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 stock-based compensation of $11.73M is the 3rd largest of the 8 companies compared; the peer median is $4.19M.
- Its year-over-year change of -65.3% is the 5th highest of 6, against a peer median of -31.7%.
- Stock-based compensation amounts to 6.0% of revenue for GERN, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.88M | -31.7% | +9.8% | 3.2% | |
| LTM Mar 2026 | $12.84M | +21.4% | +0.9% | 4.3% | |
| LTM Mar 2026 | $11.73M | -65.3% | -77.8% | 6.0% | |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Sep 2026 | $4.19M | +122.7% | +4.3% | — | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $2.01M | — | — | — |
| LTM Jun 2026 | $237K | -98.0% | +48.7% | 0.7% | |
DMRADamora Therapeutics, Inc. | LTM Jun 2024 | $0 | — | — | — |
| Peer median (excluding GERN) | $4.19M | -31.7% | +4.3% | 3.2% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| Deferred Income Tax | 191K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.08M | 8M | 19.35M | 31.32M | 88K |
| Change in Working Capital | 10.52M | 5.03M | 6.06M | (68.41M) | (68.54M) |
| Accounts Receivables | (1.04M) | (1.38M) | 1.49M | (36.89M) | (377K) |
| Inventory | 1.04M | 1.38M | 0 | (37.97M) | (77.92M) |
| Accounts Payables | (232K) | 3.5M | (4.03M) | 2.44M | 2.66M |
| Other Working Capital | 10.75M | 1.52M | 8.6M | 4.02M | 7.1M |
| Other Non-Cash Items | 984K | 626K | (10.06M) | (8.18M) | 41.99M |
| Operating Cash Flow | (95.56M) | (127.38M) | (167.74M) | (218.62M) | (111.04M) |
| Capital Expenditures | (207K) | (431K) | (830K) | (680K) | (49K) |
| Acquisitions (Net) | 1.59M | (1.23M) | 179.49M | 0 | 0 |
| Purchases of Investments | (177.43M) | (258.01M) | (475.59M) | (476.93M) | (304.42M) |
| Sales of Investments | 249.59M | 320.51M | 296.1M | 371.61M | 411.72M |
| Other Investing Activities | (1.59M) | 1.23M | (179.49M) | 0 | 0 |
| Investing Cash Flow | 71.95M | 62.07M | (180.32M) | (106M) | 107.25M |
| Debt Repayment | 24.9M | 0 | 29.7M | 34.57M | 0 |
| Common Stock Issued | 20.39M | 69.92M | 213.34M | 140.73M | 2.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.28M | 17.35M | 118.98M | 159.08M | 0 |
| Financing Cash Flow | 48.56M | 87.26M | 362.02M | 334.37M | 2.27M |
| Effect of Forex Changes | 0 | 22K | (27K) | (12K) | 87K |
| Net Change in Cash | 24.95M | 21.97M | 13.93M | 9.74M | (1.44M) |
| Free Cash Flow | (95.76M) | (127.81M) | (168.57M) | (219.3M) | (111.09M) |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.